Superworth

Royalty Pharma EPS RPRX

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$1.76
Latest quarter, Q2 FY26
$0.04
−43% on a year earlier
Fiscal year 2025
$1.67
−7% on the year before

Royalty Pharma's earnings per share was $1.76 over the twelve months to Jun 30, 2026, down 19% on a year earlier.

In its latest quarter, Q2 FY26, it was $0.04, down 43% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$1.67−7%
FY2024$1.80−20%
FY2023$2.25+72%
FY2020$1.31n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.04−43%$1.76
Q1 FY26$0.67+22%$1.79
Q4 FY25$0.38+9%$1.67
Q3 FY25$0.67−45%$1.64
Q2 FY25$0.07−70%$2.18
Q1 FY25$0.55+5400%$2.34
Q4 FY24$0.35−58%$1.80
Q3 FY24$1.21+656%$2.28
Q2 FY24$0.23−54%$1.23
Q1 FY24$0.01−99%$1.50
Q4 FY23$0.83n/a$2.25
Q3 FY23$0.16−50%n/a

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
RPRXRoyalty Pharma$1.76−19% a year
RMDResMed$10.43+10% a year
BIIBBiogen$5.65−46% a year
CNCCentene−$10.44−358% a year
ZTSZoetis$6.07+5% a year
MTDMettler-Toledo International$44.42+12% a year
ILMNIllumina$5.38−32% a year
GEHCGE HealthCare Technologies$4.36−11% a year
ONCBeOne Medicines$0.43
IDXXIDEXX Laboratories$14.22+18% a year
WATWaters$4.01−64% a year
Peer median$5.51

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.